Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.

ABSTRACT:

Objectives

To compare treatment retention between biosimilars and their originator products among first starters (etanercept, infliximab, adalimumab and rituximab), as well as after non-medical switch.

Methods

Patients with rheumatic diseases starting, for the first time, an originator or biosimilar etanercept, infliximab, adalimumab or rituximab were identified in the national Swedish Rheumatology Quality Register. Moreover, patients switching from an originator to its biosimilar were identified and individually matched to patients continuing on the originator. One-year treatment retention was calculated and hazard ratios (HR) for discontinuation with 95% CIs were estimated, adjusting for comorbidities and socio-economic factors.

Results

In total, 21 443 first treatm

SUBMITTER: Di Giuseppe D 

PROVIDER: S-EPMC9438487 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature